<SEC-DOCUMENT>0001279569-19-001329.txt : 20190605
<SEC-HEADER>0001279569-19-001329.hdr.sgml : 20190605
<ACCEPTANCE-DATETIME>20190605120026
ACCESSION NUMBER:		0001279569-19-001329
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190605
FILED AS OF DATE:		20190605
DATE AS OF CHANGE:		20190605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Canopy Growth Corp
		CENTRAL INDEX KEY:			0001737927
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38496
		FILM NUMBER:		19879139

	BUSINESS ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
		BUSINESS PHONE:		855-558-9333

	MAIL ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>canopy6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD></HEAD>
<TITLE></TITLE>
<body>


<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 6-K</B></P>



<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of June 2019.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File Number 001-38496</P>



<P STYLE="font: 20pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 20pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Canopy Growth Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name
into English)&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1 Hershey Drive</B></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Smiths Falls, Ontario</B></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>K7A 0A8</B></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive office)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Form 20-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Form 40-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"></P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 0in 1pt 0.75pt"><DIV STYLE="font-size: 1pt; border-top: gray 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%">&nbsp;</TD>
    <TD STYLE="width: 79%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 1pt solid"><B>&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 1pt solid"><B>&nbsp;&nbsp;&nbsp;&nbsp;Description&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">Ex. 99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">News
    Release dated June 5, 2019 - Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance
program</A> </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0.25in 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/0.05pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 0in 1pt 0.75pt"><DIV STYLE="font-size: 1pt; border-top: gray 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 11.25pt 0 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 8pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 50%; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 2.8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CANOPY GROWTH CORPORATION</B></FONT></TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 11%; padding-right: 0.8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-right: 0.8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 77%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid">/s/ Phil Shaer</P></TD>
    <TD STYLE="padding-bottom: 8pt; width: 11%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Phil Shaer</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Chief Legal Officer</P></TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Dated: June 5, 2019</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JUNE 5, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Spectrum Therapeutics provides update
on its global clinical research program and unveils pharmacovigilance program</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SMITHS FALLS, ON, June 5, 2019 /CNW/ -&nbsp;Spectrum
Therapeutics (&quot;Spectrum&quot;), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the &quot;Company&quot;
or &quot;Canopy Growth&quot;) is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines
through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific
team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products
for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.jpg" ALT="Spectrum Therapeutics is focused over the next 24 months to further the science of cannabinoids and provide evidence by way of clinical trials on what conditions medical cannabis can treat. (CNW Group|Spectrum Therapeutics)" STYLE="height: 119px; width: 400px"></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Spectrum Therapeutics is focused over the next
24 months to further the science of cannabinoids and provide evidence by way of clinical trials on what conditions medical cannabis
can treat. (CNW Group/Spectrum Therapeutics)</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>CLINICAL RESEARCH</B><BR>
Spectrum Therapeutics is focused over the next 24 months to further the science of cannabinoids and provide evidence by way of
clinical trials on what conditions medical cannabis can treat. This research includes product design and ingredient selection,
formulation, and safety and efficacy testing towards the development of standardized cannabis drug formulations and dose delivery
systems. Research activity is occurring in two main areas: registration trials and exploratory studies.&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Registration trials begin with phase I studies
of cannabinoid products covering a spectrum of proprietary THC and CBD ratios. These initial trials provide critical dosing and
safety data to inform subsequent phase II trials. Spectrum Therapeutics is pleased to announce that two phase I trials have already
been completed, one each in Canada and Chile.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Exploratory &quot;proof of concept&quot; studies
use a range of Spectrum products and design methodologies to explore different dose responses, and safety and efficacy signals
for target conditions. Those that show promising results will be added to the registration trial pipeline and their initial findings
will allow for optimal phase II trial design. The first proof of concept phase IIb &quot;in human&quot; clinical trial previously
announced by the Company, to evaluate the use of medical cannabis for treating insomnia, is in progress in partnership with Drs.
Julie Carrier and Alex Desautels at the Universit&eacute; de Montr&eacute;al. It is expected to be completed by calendar Q2 2020
with results announced by calendar Q3 2020.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Other proof of concept studies are currently
underway in partnership with researchers including Dr. Bernard Le Foll at the Centre for Addiction and Mental Health, Dr. Mary-Ann
Fitzcharles at McGill University, and Dr. Angela Genge at the Montreal Neurological Institute. Over twenty conditions are being
examined across these studies, including pain, sleep, and mood/anxiety disorders. Spectrum Therapeutics is also exploring areas
such as neurodegenerative disorders in addition to the previously announced research partnership with NEEKA Health Canada and the
NHL Alumni Association which is examining the efficacy of CBD-based therapies as part of a treatment for concussion symptoms. This
clinical trial is expected to register its first patients by October 2019 with preliminary results by July 2020.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Recently acquired C<SUP>3</SUP> Cannabinoid
Compound Company (&quot;C<SUP>3</SUP>&quot;) is currently progressing a clinical trial for the use of dronabinol to treat spasticity
due to multiple sclerosis. Additionally, research on the potential of medical cannabis to treat cancer-related pain is also in
the works with Beckley Canopy Therapeutics, a partnership established between U.K. drug research institute, The Beckley Foundation
and Canopy Growth. Patient registrations for this trial are expected in September 2019.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">To support its research program, Spectrum Therapeutics
is pleased to announce the appointment of Dr. Marcel Bonn-Miller as Global Clinical Scientific Director. He brings to the team
18 years of experience researching cannabinoids and their various effects, has received funding for 27 research grants, and has
led or contributed to 19 clinical trials. His work has been featured in 139 academic publications and 161 conference presentations,
and he also serves on the editorial boards of five academic journals. Dr. Bonn-Miller previously worked as Director of Cannabinoid
Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company. He is also an adjunct Assistant
Professor at the University of Pennsylvania Perelman School of Medicine, known for his work examining the potential of cannabis
in treating post-traumatic stress disorder.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Dr. Bonn-Miller will be supported by Hunter
Land and Drs. Ryan Lanier and Erica Peters as Associate Directors. Land was instrumental in bringing the first cannabis-derived
CBD medicine developed for patients with treatment-resistant forms of epilepsy, including Dravet and Lennox-Gastaut syndromes,
to FDA approval. Dr. Peters was the lead clinical cannabis scientist for four years at Battelle, the world's largest non-profit
research and development organization, and Dr. Lanier worked for Analgesic Solutions where he consulted on the development of pain
medications for FDA approval.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>PHARMACOVIGILANCE</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In the interest of patient safety and good
clinical practice, Spectrum Therapeutics is pleased to announce the implementation of a unique global pharmacovigilance program
to capture and document adverse events reported from the worldwide use of its medical cannabis products in addition to the Company's
Canadian recreational cannabis brands including Tweed and DNA Genetics, and its CBD product offerings.&nbsp;&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Pharmacovigilance, also known as drug safety,
is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects
from the use of pharmaceutical products. While Spectrum Therapeutics and Canopy Growth were already reporting any adverse reactions
to its cannabis products as per Health Canada regulations, the launch of this global pharmacovigilance program ensures that all
employees are trained on how to identify and report adverse events. The Company's internal Pharmacovigilance team is responsible
for analyzing and entering events into a global safety database compliant with regional regulatory requirements.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">A global independent safety monitoring board
chaired by Professor Yola Moride at the Universit&eacute; de Montr&eacute;al will periodically review adverse event summaries and
advise the Spectrum Therapeutics scientific team regarding product safety and clinical trial design.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;We believe that this strategic approach
to global clinical research, in collaboration with outstanding investigators and institutions, and supported by our first-rate
team of scientists, will generate innovative products for a number of indications with significant unmet needs,&quot; commented
Dr. Mark Ware, Chief Medical Officer, Canopy Growth. &quot;We are also pleased to announce the launch of our global pharmacovigilance
program whereby every one of our 3000+ staff worldwide are trained in reporting adverse events. It's an important step towards
establishing drug safety and will advance our efforts to provide patients with accepted, clinically validated cannabis medicines
while transparently demonstrating the relative risks of cannabis.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Here's to (Clinically Validated) Future Growth.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>About Canopy Growth Corporation</U></B><BR>
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct
brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's
subsidiary, Storz &amp; Bickel GMbH &amp; Co. KG. From product and process innovation to market execution, Canopy Growth is driven
by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
The Company has operations in over a dozen countries across five continents.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company's medical division, Spectrum Therapeutics
is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding
of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics
sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol
under the brand Bionorica Ethics.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company operates retail stores across Canada
under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and
loyal following by focusing on quality products and meaningful customer relationships.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">From our historic public listing on the Toronto
Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through
leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including
cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation
Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.4 million square feet of production
capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Notice Regarding Forward Looking Statements</B><BR>
This news release contains &quot;forward-looking statements&quot; within the meaning of the United States Private Securities Litigation
Reform Act of 1995 and &quot;forward-looking information&quot; within the meaning of applicable Canadian securities legislation.
Often, but not always, forward-looking statements and information can be identified by the use of words such as &quot;plans&quot;,
&quot;expects&quot; or &quot;does not expect&quot;, &quot;is expected&quot;, &quot;estimates&quot;, &quot;intends&quot;, &quot;anticipates&quot;
or &quot;does not anticipate&quot;, or &quot;believes&quot;, or variations of such words and phrases or state that certain actions,
events or results &quot;may&quot;, &quot;could&quot;, &quot;would&quot;, &quot;might&quot; or &quot;will&quot; be taken, occur
or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements or information contained
in this news release. Examples of such statements include &quot;expected to be completed by Q2 2020 with results announced by Q3
2020&quot;, and &quot;those that show promising results will be added to the registration trial pipeline&quot;. Risks, uncertainties
and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities
to differ materially from those expressed or implied by such forward-looking information, including clinical trial results, product
supply, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions
and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable,
undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed
time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as
of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information
or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities
laws.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_002.jpg" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content to download multimedia:http://www.prnewswire.com/news-releases/spectrum-therapeutics-provides-update-on-its-global-clinical-research-program-and-unveils-pharmacovigilance-program-300862386.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Spectrum Therapeutics</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/June2019/05/c9948.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001737927</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Caitlin O'Hara, Media Relations,
Caitlin.ohara@canopygrowth.com, 613-291-3239; Tyler Burns, Investor Relations, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Spectrum Therapeutics</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 07:00e 05-JUN-19</P>



<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></p>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[0*P4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=6T@5&AE<F%P975T:6-S*1P"6@ ,4TU)5$A3($9!3$Q3' )T  $ ' )E  $
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MD:$7,U*CL<'1%B5C97*"LPDD)BE#15-DDJ2R\/'_Q  ; 0$  P$! 0$
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MD?[V<@58<.T'7$-MJ<<6E"$C*E*. !\S7U7(WBWTEO/9/"5N''U5O+#U)"1
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MTJ%-8D72X)+2E*T%0I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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' *4I0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ,  P# 2(  A$! Q$!_\0
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?L94\=#@5IJH50HZ 8%8TXM3DWU.BK.+I02Z>7ZG_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
